WO2010062383A3 - Polypeptides de récepteur stabilisés et leurs utilisations - Google Patents
Polypeptides de récepteur stabilisés et leurs utilisations Download PDFInfo
- Publication number
- WO2010062383A3 WO2010062383A3 PCT/US2009/006252 US2009006252W WO2010062383A3 WO 2010062383 A3 WO2010062383 A3 WO 2010062383A3 US 2009006252 W US2009006252 W US 2009006252W WO 2010062383 A3 WO2010062383 A3 WO 2010062383A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- receptor polypeptides
- variants
- iib receptor
- activin
- activin iib
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108010059616 Activins Proteins 0.000 title abstract 2
- 239000000488 activin Substances 0.000 title abstract 2
- 102000005606 Activins Human genes 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 abstract 1
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 abstract 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 abstract 1
- 102100026818 Inhibin beta E chain Human genes 0.000 abstract 1
- 206010028289 Muscle atrophy Diseases 0.000 abstract 1
- 108010056852 Myostatin Proteins 0.000 abstract 1
- 108010023082 activin A Proteins 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000000585 muscular atrophy Diseases 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
Abstract
Priority Applications (30)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK09761055.4T DK2370463T3 (en) | 2008-11-26 | 2009-11-24 | STABILIZED VARIANT OF activin IIB RECEPTOR |
EP09761055.4A EP2370463B1 (fr) | 2008-11-26 | 2009-11-24 | Une variant stabilisé d'activin iib récepteur |
LTEP09761055.4T LT2370463T (lt) | 2008-11-26 | 2009-11-24 | Stabilizuotas aktivino iib receptoriaus variantas |
KR1020177007651A KR101778134B1 (ko) | 2008-11-26 | 2009-11-24 | 액티빈 iib 수용체 폴리펩타이드의 변이체 및 이의 용도 |
SG2011037777A SG171813A1 (en) | 2008-11-26 | 2009-11-24 | Variants of activin iib receptor polypeptides and uses thereof |
AU2009320364A AU2009320364B2 (en) | 2008-11-26 | 2009-11-24 | Variants of activin IIB receptor polypeptides and uses thereof |
EP16179980.4A EP3101029B1 (fr) | 2008-11-26 | 2009-11-24 | Variants de polypeptides récepteurs iib d'activine et leurs utilisations |
KR1020177025044A KR20170105124A (ko) | 2008-11-26 | 2009-11-24 | 액티빈 iib 수용체 폴리펩타이드의 변이체 및 이의 용도 |
JP2011538599A JP5611222B2 (ja) | 2008-11-26 | 2009-11-24 | アクチビンiib受容体ポリペプチドの変異体及びその使用 |
CN200980147945.3A CN102245634B (zh) | 2008-11-26 | 2009-11-24 | 激活素iib受体多肽的变异体及其用途 |
EA201100832A EA201100832A1 (ru) | 2008-11-26 | 2009-11-24 | Варианты полипептидов рецептора iib активина и их применение |
ES09761055.4T ES2600491T3 (es) | 2008-11-26 | 2009-11-24 | Una variante estabilizada de receptor IIB de activina |
UAA201107872A UA107921C2 (en) | 2008-11-26 | 2009-11-24 | Variants of polypeptide of receptor ivr activin and their use |
BRPI0920962A BRPI0920962A2 (pt) | 2008-11-26 | 2009-11-24 | variantes de polipeptídeos receptores de activina iib e usos dos mesmos |
SI200931546A SI2370463T1 (sl) | 2008-11-26 | 2009-11-24 | Stabilizirana varianta IIB receptorja aktivina |
CA2743850A CA2743850C (fr) | 2008-11-26 | 2009-11-24 | Variantes des polypeptides du recepteur iib de l'activine et leurs utilisations |
CR20160443A CR20160443A (es) | 2008-11-26 | 2009-11-24 | Variantes de polipéptidos receptores de activina iib y aplicaciones de éstos (divisional) |
RS20160909A RS55369B1 (sr) | 2008-11-26 | 2009-11-24 | Stabilizovana varijanta aktivin iib receptora |
MX2011005505A MX2011005505A (es) | 2008-11-26 | 2009-11-24 | Variantes de polipeptidos receptores de activina iib y aplicaciones de estos. |
MA33960A MA32936B1 (fr) | 2008-11-26 | 2009-11-24 | Polypeptides de recepteur stabilises et leurs utilisations |
MEP-2016-243A ME02652B (fr) | 2008-11-26 | 2009-11-24 | Une variant stabilisé d'activin iib récepteur |
KR1020117014720A KR101720143B1 (ko) | 2008-11-26 | 2009-11-24 | 액티빈 iib 수용체 폴리펩타이드의 변이체 및 이의 용도 |
IL212773A IL212773A (en) | 2008-11-26 | 2011-05-08 | And variants of activin iib receptor polypeptides and their uses |
TN2011000238A TN2011000238A1 (en) | 2008-11-26 | 2011-05-12 | Variants of activin iib receptor polypeptides and uses thereof |
ZA2011/04648A ZA201104648B (en) | 2008-11-26 | 2011-06-23 | Variants of activin iib receptor polypeptides and uses thereof |
HK12103250.5A HK1162545A1 (zh) | 2008-11-26 | 2012-04-02 | 種穩定的活化素 受體變體 |
IL248128A IL248128A0 (en) | 2008-11-26 | 2016-09-29 | Stabilized receptor polypeptides and their use |
HRP20161450TT HRP20161450T1 (hr) | 2008-11-26 | 2016-11-03 | Stabilizirana varijanta aktivinskog receptora iib |
SM201600417T SMT201600417B (it) | 2008-11-26 | 2016-11-16 | Una variante stabilizzata di recettore di attivina iib |
CY20161101175T CY1118754T1 (el) | 2008-11-26 | 2016-11-16 | Μια σταθεροποιημενη παραλλαγη υποδοχεα ακτιβινης ιιb |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20025008P | 2008-11-26 | 2008-11-26 | |
US61/200,250 | 2008-11-26 | ||
US25906009P | 2009-11-06 | 2009-11-06 | |
US61/259,060 | 2009-11-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010062383A2 WO2010062383A2 (fr) | 2010-06-03 |
WO2010062383A3 true WO2010062383A3 (fr) | 2010-08-19 |
Family
ID=41693455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/006252 WO2010062383A2 (fr) | 2008-11-26 | 2009-11-24 | Polypeptides de récepteur stabilisés et leurs utilisations |
Country Status (38)
Country | Link |
---|---|
US (5) | US8410043B2 (fr) |
EP (2) | EP3101029B1 (fr) |
JP (3) | JP5611222B2 (fr) |
KR (3) | KR101720143B1 (fr) |
CN (2) | CN102245634B (fr) |
AR (1) | AR074397A1 (fr) |
AU (1) | AU2009320364B2 (fr) |
BR (1) | BRPI0920962A2 (fr) |
CA (2) | CA2997971A1 (fr) |
CL (1) | CL2011001239A1 (fr) |
CO (1) | CO6382163A2 (fr) |
CR (2) | CR20160443A (fr) |
CY (1) | CY1118754T1 (fr) |
DK (1) | DK2370463T3 (fr) |
EA (2) | EA201791940A3 (fr) |
ES (1) | ES2600491T3 (fr) |
HK (1) | HK1162545A1 (fr) |
HR (1) | HRP20161450T1 (fr) |
HU (1) | HUE032090T2 (fr) |
IL (2) | IL212773A (fr) |
LT (1) | LT2370463T (fr) |
MA (1) | MA32936B1 (fr) |
ME (1) | ME02652B (fr) |
MX (1) | MX2011005505A (fr) |
MY (1) | MY159483A (fr) |
NZ (2) | NZ627111A (fr) |
PE (2) | PE20150680A1 (fr) |
PL (1) | PL2370463T3 (fr) |
PT (1) | PT2370463T (fr) |
RS (1) | RS55369B1 (fr) |
SG (2) | SG10201703067QA (fr) |
SI (1) | SI2370463T1 (fr) |
SM (1) | SMT201600417B (fr) |
TN (1) | TN2011000238A1 (fr) |
TW (1) | TWI486166B (fr) |
UA (1) | UA107921C2 (fr) |
WO (1) | WO2010062383A2 (fr) |
ZA (1) | ZA201104648B (fr) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
AU2006318449B2 (en) | 2005-11-23 | 2012-07-05 | Acceleron Pharma Inc. | Activin-actRIIa antagonists and uses for promoting bone growth |
CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
CA2677007A1 (fr) | 2007-02-01 | 2008-08-07 | Acceleron Pharma Inc. | Antagonistes de l'activine-actriia et leurs utilisations dans le traitement ou la prevention du cancer du sein |
TWI782836B (zh) | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
TWI667038B (zh) | 2007-02-09 | 2019-08-01 | 美商艾瑟勒朗法瑪公司 | 包含ActRIIa-Fc融合蛋白的醫藥組合物;ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途;ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途 |
US8501678B2 (en) | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
US7960343B2 (en) | 2007-09-18 | 2011-06-14 | Acceleron Pharma Inc. | Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion |
SI3750552T1 (sl) | 2008-08-14 | 2023-10-30 | Acceleron Pharma Inc. | GDF pasti |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
MA32936B1 (fr) * | 2008-11-26 | 2012-01-02 | Amgen Inc | Polypeptides de recepteur stabilises et leurs utilisations |
CN107267520A (zh) | 2009-06-12 | 2017-10-20 | 阿塞勒隆制药公司 | 截短的actriib‑fc融合蛋白 |
US8710016B2 (en) | 2009-11-17 | 2014-04-29 | Acceleron Pharma, Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
EP2591097A1 (fr) * | 2010-07-06 | 2013-05-15 | Novartis AG | Compositions immunogènes dérivées d'un norovirus et méthodes |
NZ608206A (en) | 2010-08-16 | 2015-02-27 | Amgen Inc | Antibodies that bind myostatin, compositions and methods |
CN103298832A (zh) | 2010-11-08 | 2013-09-11 | 阿塞勒隆制药公司 | Actriia结合剂及其用途 |
CA2859504A1 (fr) * | 2011-12-19 | 2013-07-18 | Amgen Inc. | Variants polypeptidiques du recepteur de l'activine, seuls ou en combinaison avec une chimiotherapie, et leurs utilisations |
EA201492282A1 (ru) | 2012-06-11 | 2015-07-30 | Амген Инк. | Антагонистические антигенсвязывающие белки к двум рецепторам и их применение |
CA2890217C (fr) | 2012-11-02 | 2021-07-20 | Yifu FANG | Antagonistes d'activine-actrii et utilisations pour le traitement de troubles osseux et autres |
SG11201505960VA (en) * | 2013-02-01 | 2015-08-28 | Santa Maria Biotherapeutics Inc | Administration of an anti-activin-a compound to a subject |
US20140220033A1 (en) * | 2013-02-01 | 2014-08-07 | Santa Maria Biotherapeutics, Inc. | Administration of an Anti-Activin-A Compound to a Subject |
TW201920262A (zh) * | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素a之抗體及其用途 |
CN104693270B (zh) * | 2013-12-10 | 2018-10-16 | 清华大学 | 一种用于融合蛋白的连接肽 |
US20160333418A1 (en) * | 2014-01-14 | 2016-11-17 | Santa Maria Biotherapeutics, Inc. | Activin Inhibitor Response Prediction and Uses for Treatment |
WO2015192111A1 (fr) | 2014-06-13 | 2015-12-17 | Acceleron Pharma, Inc. | Méthodes et compositions de traitement d'ulcères |
MX2016016281A (es) * | 2014-06-13 | 2017-03-31 | Santa Maria Biotherapeutics Inc | Polipeptidos receptores formulados y metodos relacionados. |
MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
HUE054180T2 (hu) * | 2015-04-06 | 2021-08-30 | Acceleron Pharma Inc | Egykarú I. típusú és II. típusú receptorral rendelkezõ fúziós fehérjék, illetve ezek alkalmazásai |
EP3828199A1 (fr) | 2015-04-06 | 2021-06-02 | Acceleron Pharma Inc. | Hétéromultimères alk7: actriib et leurs utilisations |
MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
PL3286206T3 (pl) | 2015-04-22 | 2021-09-13 | Biogen Ma Inc. | Nowe hybrydowe białka pułapki na ligand actriib do leczenia chorób powodujących zanik mięśni |
AU2017230091B2 (en) | 2016-03-10 | 2022-04-07 | Acceleron Pharma Inc. | Activin type 2 receptor binding proteins and uses thereof |
CN110678195A (zh) | 2016-10-05 | 2020-01-10 | 阿塞勒隆制药公司 | ALK4:ActRIIB异多聚体及其用途 |
WO2018089706A2 (fr) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Variants du récepteur de l'activine de type iia et leurs méthodes d'utilisation |
JP7258021B2 (ja) | 2017-11-09 | 2023-04-14 | ケロス セラピューティクス インコーポレイテッド | アクチビンIIa型受容体変異体を含む医薬組成物 |
AU2019206634A1 (en) | 2018-01-12 | 2020-07-23 | Keros Therapeutics, Inc. | Activin receptor type IIB variants and methods of use thereof |
CN109320597B (zh) * | 2018-10-26 | 2021-10-26 | 中国农业科学院特产研究所 | 狐亚科激活素a蛋白及其制备与应用 |
WO2023108137A1 (fr) | 2021-12-10 | 2023-06-15 | Biogen Ma Inc. | Protéines actriib modifiées et leurs procédés d'utilisation |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
WO2007053775A1 (fr) * | 2005-11-01 | 2007-05-10 | Amgen Inc. | Nouveau recepteur d'activine et utilisations de celui-ci |
WO2008097541A2 (fr) * | 2007-02-02 | 2008-08-14 | Acceleron Pharma Inc. | Variantes dérivées de actriib, et leurs utilisations |
WO2008109167A2 (fr) * | 2007-03-06 | 2008-09-12 | Amgen Inc. | Polypeptides de récepteur d'activine variants, et leurs utilisations |
WO2008113185A1 (fr) * | 2007-03-19 | 2008-09-25 | National Research Counsil Of Canada | Antagonistes de ligands et leurs utilisations |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
EP0143949B1 (fr) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Composition pharmaceutique contenant de l'urokinase |
US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
US5750375A (en) | 1988-01-22 | 1998-05-12 | Zymogenetics, Inc. | Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions |
AU648505B2 (en) | 1989-05-19 | 1994-04-28 | Amgen, Inc. | Metalloproteinase inhibitor |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
US6162896A (en) | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
US5885794A (en) | 1991-05-10 | 1999-03-23 | The Salk Institute For Biological Studies | Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily |
US20050186593A1 (en) | 1991-05-10 | 2005-08-25 | The Salk Institute For Biological Studies | Cloning and recombinant production of CRF receptor(s) |
US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
US6153407A (en) | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
US6465239B1 (en) | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
US6607884B1 (en) | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
WO1994021681A1 (fr) | 1993-03-19 | 1994-09-29 | Johns Hopkins University School Of Medicine | Facteur gde8 de differentiation de croissance |
US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
US5863738A (en) | 1994-04-29 | 1999-01-26 | Creative Biomolecules, Inc. | Methods of antagonizing OP-1 binding to a cell surface receptor utilizing ALK polypeptides |
US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
WO2000029581A1 (fr) | 1998-11-13 | 2000-05-25 | Immunex Corporation | Polypeptides de lymphopoietine de stroma thymique humain (tslp), adn et polypeptides associes |
CA2359242C (fr) | 1999-01-21 | 2009-12-08 | Metamorphix, Inc. | Inhibiteurs de facteurs de differenciation de la croissance et leurs utilisations |
JP4487376B2 (ja) | 2000-03-31 | 2010-06-23 | 味の素株式会社 | 腎疾患治療剤 |
GB0209896D0 (en) | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
MEP57508A (en) | 2002-12-20 | 2011-05-10 | Amgen Inc | Binding agents which inhibit myostatin |
MXPA05012965A (es) | 2003-06-02 | 2006-03-09 | Wyeth Corp | Uso de inhibidores de miostatina (gdf8) en conjuncion con corticoesteroides para el tratamiento de desordenes neuromusculares y composiciones farmaceuticas para ello. |
ES2372495T3 (es) | 2003-11-13 | 2012-01-20 | Hanmi Holdings Co., Ltd | Método para la producción en masa de la región constante de inmunoglobulina. |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
ES2426005T3 (es) | 2004-07-23 | 2013-10-18 | Acceleron Pharma Inc. | Polipéptidos del receptor ACTRII, procedimientos y composiciones |
EP1778275A2 (fr) | 2004-08-12 | 2007-05-02 | Wyeth | Traitement combine du diabete, de l'obesite et de maladies cardiovasculaires, faisant appel a des inhibiteurs de gdf-8 |
SI1797127T1 (sl) | 2004-09-24 | 2017-09-29 | Amgen Inc. | Modificirane fc-molekule |
KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물 |
MY164457A (en) | 2005-09-07 | 2017-12-15 | Amgen Fremont Inc | Human monoclonal antibodies to activin receptor-like kinase-1 |
BRPI0708368A2 (pt) * | 2006-03-02 | 2011-05-24 | Ishihara Sangyo Kaisha | composição herbicida sólida |
CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
CN104524548A (zh) | 2006-12-18 | 2015-04-22 | 阿塞勒隆制药公司 | 活化素-actrii拮抗剂及在提高红细胞水平中的用途 |
US8501678B2 (en) * | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
US7960343B2 (en) | 2007-09-18 | 2011-06-14 | Acceleron Pharma Inc. | Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion |
EP2217261B1 (fr) | 2007-11-09 | 2015-10-07 | Genentech, Inc. | Composition comprenant des antagonistes à l'activine réceptor-like kinase (alk-1) et procédés d'utilisation |
KR20220002710A (ko) | 2008-06-26 | 2022-01-06 | 악셀레론 파마 인코포레이티드 | 액티빈-actriia 길항물질을 투약하는 방법 및 치료된 환자의 모니터링 |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
SI3750552T1 (sl) | 2008-08-14 | 2023-10-30 | Acceleron Pharma Inc. | GDF pasti |
MA32936B1 (fr) * | 2008-11-26 | 2012-01-02 | Amgen Inc | Polypeptides de recepteur stabilises et leurs utilisations |
CA2749544A1 (fr) | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Procedes permettant d'augmenter l'adiponectine |
EA027071B1 (ru) | 2009-04-27 | 2017-06-30 | Новартис Аг | АНТИТЕЛО К ActRIIB И СОДЕРЖАЩАЯ ЕГО КОМПОЗИЦИЯ |
EP3845239A1 (fr) | 2009-06-08 | 2021-07-07 | Acceleron Pharma Inc. | Utilisation de protéines anti-actriib pour l'augmentation d'adipocytes thermogènes |
US20120295814A1 (en) | 2010-01-08 | 2012-11-22 | The Brigham And Women's Hospital, Inc. | CA-125 Immune Complexes as Biomarkers of Ovarian Cancer |
CA2794513A1 (fr) | 2010-03-31 | 2011-10-06 | Aeterna Zentaris Gmbh | Perifosine et capecitabine en tant que traitement combine du cancer |
CN103298832A (zh) | 2010-11-08 | 2013-09-11 | 阿塞勒隆制药公司 | Actriia结合剂及其用途 |
WO2013106715A1 (fr) | 2012-01-13 | 2013-07-18 | Allergan, Inc. | Gels de collagène et d'acide hyaluronique réticulés destinés à améliorer la viabilité d'une greffe de tissu et l'augmentation de tissu mou |
WO2013180295A1 (fr) | 2012-06-01 | 2013-12-05 | 日本電信電話株式会社 | Procédé de traitement de transfert de paquets et dispositif de traitement de transfert de paquets |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2009
- 2009-11-24 MA MA33960A patent/MA32936B1/fr unknown
- 2009-11-24 AR ARP090104527A patent/AR074397A1/es not_active Application Discontinuation
- 2009-11-24 CA CA2997971A patent/CA2997971A1/fr not_active Abandoned
- 2009-11-24 CA CA2743850A patent/CA2743850C/fr not_active Expired - Fee Related
- 2009-11-24 SG SG10201703067QA patent/SG10201703067QA/en unknown
- 2009-11-24 EA EA201791940A patent/EA201791940A3/ru unknown
- 2009-11-24 CN CN200980147945.3A patent/CN102245634B/zh not_active Expired - Fee Related
- 2009-11-24 AU AU2009320364A patent/AU2009320364B2/en not_active Ceased
- 2009-11-24 UA UAA201107872A patent/UA107921C2/ru unknown
- 2009-11-24 LT LTEP09761055.4T patent/LT2370463T/lt unknown
- 2009-11-24 PE PE2015000401A patent/PE20150680A1/es not_active Application Discontinuation
- 2009-11-24 MY MYPI2011002346A patent/MY159483A/en unknown
- 2009-11-24 KR KR1020117014720A patent/KR101720143B1/ko active IP Right Grant
- 2009-11-24 SG SG2011037777A patent/SG171813A1/en unknown
- 2009-11-24 JP JP2011538599A patent/JP5611222B2/ja not_active Expired - Fee Related
- 2009-11-24 PE PE2011001077A patent/PE20120206A1/es not_active Application Discontinuation
- 2009-11-24 PT PT97610554T patent/PT2370463T/pt unknown
- 2009-11-24 EP EP16179980.4A patent/EP3101029B1/fr active Active
- 2009-11-24 NZ NZ627111A patent/NZ627111A/en not_active IP Right Cessation
- 2009-11-24 BR BRPI0920962A patent/BRPI0920962A2/pt not_active IP Right Cessation
- 2009-11-24 WO PCT/US2009/006252 patent/WO2010062383A2/fr active Application Filing
- 2009-11-24 NZ NZ604818A patent/NZ604818A/en not_active IP Right Cessation
- 2009-11-24 SI SI200931546A patent/SI2370463T1/sl unknown
- 2009-11-24 EA EA201100832A patent/EA201100832A1/ru unknown
- 2009-11-24 ME MEP-2016-243A patent/ME02652B/fr unknown
- 2009-11-24 HU HUE09761055A patent/HUE032090T2/en unknown
- 2009-11-24 ES ES09761055.4T patent/ES2600491T3/es active Active
- 2009-11-24 PL PL09761055T patent/PL2370463T3/pl unknown
- 2009-11-24 CR CR20160443A patent/CR20160443A/es unknown
- 2009-11-24 KR KR1020177025044A patent/KR20170105124A/ko active IP Right Grant
- 2009-11-24 DK DK09761055.4T patent/DK2370463T3/en active
- 2009-11-24 MX MX2011005505A patent/MX2011005505A/es active IP Right Grant
- 2009-11-24 RS RS20160909A patent/RS55369B1/sr unknown
- 2009-11-24 KR KR1020177007651A patent/KR101778134B1/ko active IP Right Grant
- 2009-11-24 EP EP09761055.4A patent/EP2370463B1/fr active Active
- 2009-11-24 CN CN201410462932.8A patent/CN104371024A/zh active Pending
- 2009-11-25 US US12/626,375 patent/US8410043B2/en active Active
- 2009-11-26 TW TW098140431A patent/TWI486166B/zh not_active IP Right Cessation
-
2011
- 2011-05-08 IL IL212773A patent/IL212773A/en not_active IP Right Cessation
- 2011-05-12 TN TN2011000238A patent/TN2011000238A1/fr unknown
- 2011-05-26 CL CL2011001239A patent/CL2011001239A1/es unknown
- 2011-06-23 ZA ZA2011/04648A patent/ZA201104648B/en unknown
- 2011-06-23 CO CO11079058A patent/CO6382163A2/es not_active Application Discontinuation
- 2011-06-24 CR CR20110364A patent/CR20110364A/es unknown
-
2012
- 2012-04-02 HK HK12103250.5A patent/HK1162545A1/zh not_active IP Right Cessation
-
2013
- 2013-02-25 US US13/775,756 patent/US9273114B2/en active Active
-
2014
- 2014-09-02 JP JP2014177598A patent/JP5969557B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-22 US US15/004,375 patent/US10308704B2/en active Active
- 2016-07-07 JP JP2016134684A patent/JP2016199577A/ja not_active Ceased
- 2016-09-29 IL IL248128A patent/IL248128A0/en unknown
- 2016-11-03 HR HRP20161450TT patent/HRP20161450T1/hr unknown
- 2016-11-16 CY CY20161101175T patent/CY1118754T1/el unknown
- 2016-11-16 SM SM201600417T patent/SMT201600417B/it unknown
-
2019
- 2019-04-18 US US16/388,561 patent/US11685770B2/en active Active
-
2023
- 2023-06-07 US US18/206,963 patent/US20230295267A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
WO2007053775A1 (fr) * | 2005-11-01 | 2007-05-10 | Amgen Inc. | Nouveau recepteur d'activine et utilisations de celui-ci |
WO2008097541A2 (fr) * | 2007-02-02 | 2008-08-14 | Acceleron Pharma Inc. | Variantes dérivées de actriib, et leurs utilisations |
WO2008109167A2 (fr) * | 2007-03-06 | 2008-09-12 | Amgen Inc. | Polypeptides de récepteur d'activine variants, et leurs utilisations |
WO2008113185A1 (fr) * | 2007-03-19 | 2008-09-25 | National Research Counsil Of Canada | Antagonistes de ligands et leurs utilisations |
Non-Patent Citations (1)
Title |
---|
THOMPSON T B ET AL: "Structures of an ActRIIB:activin A complex reveal a novel binding mode for TGF-beta ligand:receptor interactions", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 22, no. 7, 1 April 2003 (2003-04-01), pages 1555 - 1566, XP002366299, ISSN: 0261-4189 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010062383A3 (fr) | Polypeptides de récepteur stabilisés et leurs utilisations | |
WO2008109167A3 (fr) | Polypeptides de récepteur d'activine variants, et leurs utilisations | |
TN2014000270A1 (en) | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof | |
ATE554101T1 (de) | Neuer activinrezeptor und anwendungen davon | |
WO2008121767A3 (fr) | Polypeptides cousus | |
WO2010107825A3 (fr) | Compositions et procedes comprenant des variants d'epissage d'histidyl-arnt synthetase presentant des activites biologiques non canoniques | |
WO2010009368A3 (fr) | Compositions pour la détection et le traitement du cancer colorectal | |
WO2009012176A3 (fr) | Methodes et compositions de traitement des maladies cerebrales | |
WO2007041635A3 (fr) | Variants de fc dotés de propriétés de liaison aux récepteurs fc optimisées | |
ZA201001434B (en) | 2-aza-bicyclo[3.3.0]octane derivatives | |
WO2009108860A8 (fr) | Procédés et compositions à base de micro-arn permettant de diagnostiquer, de pronostiquer et de traiter des troubles liés à la prostate | |
EP2215579A4 (fr) | Authentification biométrique utilisant l' il | |
IL212589A0 (en) | Binding proteins inhibiting the vegf-a receptor interaction | |
WO2007089669A3 (fr) | Procédés de préparation de composés | |
WO2008097561A8 (fr) | Oxabicycloheptanes et oxabicycloheptènes, leur préparation et leur utilisation | |
WO2012106725A3 (fr) | Procédés et compositions pour traitement de troubles oculaires | |
WO2007036945A3 (fr) | Variants d'epissure du recepteur du facteur de croissance des hepatocytes et methodes d'utilisation | |
HK1208701A1 (en) | Means for inhibiting the expression of protein kinase | |
WO2008112290A3 (fr) | Utilisation du récepteur ephb4 comme marqueur diagnostique et cible thérapeutique dans le cancer de l'ovaire | |
WO2008086035A3 (fr) | Rapporteur de fusion d'hydrolase mutante divisée et utilisations de celui-ci | |
WO2010111516A3 (fr) | Compositions et procédés d'inhibition de biofilms | |
MX303262B (es) | Composicion de locion para uso personal. | |
WO2009023125A9 (fr) | Neuronostatine et ses utilisations | |
WO2008142693A3 (fr) | Régulation de la myélination par des molécules de type nectine (necl) | |
MY155313A (en) | Variant activin receptor polypeptides and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980147945.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09761055 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 212773 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 592828 Country of ref document: NZ Ref document number: 2009320364 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2743850 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: /P/2011/00006 Country of ref document: BW |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12011501002 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 001077-2011 Country of ref document: PE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011538599 Country of ref document: JP Ref document number: MX/A/2011/005505 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2009320364 Country of ref document: AU Date of ref document: 20091124 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2011000401 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4750/DELNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11079058 Country of ref document: CO Ref document number: 201100832 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 20117014720 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2011-000364 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: a201107872 Country of ref document: UA |
|
REEP | Request for entry into the european phase |
Ref document number: 2009761055 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009761055 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 000401-2015 Country of ref document: PE |
|
ENP | Entry into the national phase |
Ref document number: PI0920962 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110526 |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2016-000443 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 248128 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2016/0909 Country of ref document: RS |